Leveraging its proprietary Inositune platform, Inositec pioneers the development of life-saving small molecule drugs based on inositol phosphate. By modifying the chemical and physical properties of inositol phosphate analogs, the company tailors molecules with favorable drug-like properties for treating cardiovascular and renal calcification disorders. Their lead program, INS-3001, is an inhibitor for aortic valve stenosis, addressing a high-unmet medical need. Founded in 2015 as a spin-off of ETH Zurich, Inositec's innovative approach attracted the attention of Vifor Pharma, leading to its acquisition in 2021.